Abstract: Selinexor (KPT-330) is a first-in-class, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) that specifically targets the exportin-1 (XPO1/CRM1) protein. By blocking XPO1, selinexor forces the nuclear retention and activation of tumor suppressor proteins and inhibits the translation of key oncoproteins, leading to cell cycle arrest and apoptosis in malignant cells. While the targeted research direction is myelofibrosis, the provided literature predominantly highlights selinexor's extensive clinical evaluation and regulatory approval for relapsed/refractory multiple myeloma (RRMM) and its emerging role in acute myeloid leukemia (AML) and solid tumors. This review synthesizes the pharmacological activity, molecular mechanisms, structure-activity relationships, and current limitations of selinexor based on the provided literature, offering insights into how its efficacy in related hematological and myeloid malignancies could inform future therapeutic strategies.
1. Introduction
Selinexor (KPT-330) is a potent, slowly reversible, first-in-class small molecule inhibitor of nuclear export [4]. Its primary target is exportin-1 (XPO1, also known as CRM1), a key regulatory protein responsible for the nuclear-to-cytoplasmic transport of over 200 cargo proteins, including major tumor suppressors and growth regulators [1][8]. XPO1 is frequently overexpressed in a wide variety of hematological malignancies and solid tumors, and this overexpression strongly correlates with advanced disease stages, therapy resistance, and inferior patient survival [1][4].
Although the specific research direction of this review targets myelofibrosis, the provided literature focuses on the clinical and preclinical development of selinexor in related hematological disorders, most notably multiple myeloma (MM), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL) [3][5]. Because myelofibrosis shares overlapping pathophysiological features with other myeloid neoplasms like AML, understanding selinexor's mechanism of action, toxicity profile (such as its impact on megakaryopoiesis), and synergistic potential in these related cancers provides a critical foundation for its potential future application in myeloproliferative neoplasms.
2. Pharmacological Activity
Selinexor has demonstrated robust pharmacological activity, particularly in heavily pretreated hematological malignancies. In 2019, the US Food and Drug Administration (FDA) granted accelerated approval for selinexor in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who are penta-refractory (refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody) [2][4]. This was based on the phase IIb STORM trial, which showed an overall response rate (ORR) of 26% and a median overall survival of 8.6 months in this highly refractory population [4][7].
Subsequent trials have expanded its utility. The phase III BOSTON trial demonstrated that combining selinexor with bortezomib and dexamethasone (SVd) significantly prolonged progression-free survival (PFS) to 13.93 months compared to 9.46 months with bortezomib and dexamethasone alone [4][8]. The multi-arm STOMP trial has also shown high efficacy when selinexor is combined with carfilzomib, pomalidomide, or daratumumab [4][8].
In acute myeloid leukemia (AML), phase I/II trials of selinexor as a single agent or in combination with standard chemotherapy (e.g., high-dose cytarabine, mitoxantrone, or decitabine) have shown promising response rates, including significant reductions in bone marrow blasts and improved PFS [3][5]. Selinexor has also been evaluated in solid tumors such as glioblastoma, liposarcoma, and breast cancer; however, single-agent efficacy in solid tumors has been modest, driving the focus toward combination regimens [5][10].
3. Molecular Mechanism of Action
The anti-tumor activity of selinexor is driven by its ability to block XPO1-mediated nuclear export. This blockade triggers several interconnected molecular mechanisms:
1. Nuclear Retention of Tumor Suppressor Proteins (TSPs): Selinexor forces the nuclear accumulation and functional reactivation of key TSPs, including p53, p21, p27, and FOXO3A. This leads to cell cycle arrest and the induction of apoptosis in malignant cells [3][4].
2. Inhibition of Oncoprotein Translation: XPO1 is responsible for exporting the eukaryotic translation initiation factor 4E (eIF4E) bound to specific mRNAs. By inhibiting XPO1, selinexor prevents the cytoplasmic localization and subsequent translation of proto-oncogenic mRNAs, leading to the downregulation of oncoproteins such as c-MYC, BCL-2, and Mcl-1 [4][11].
3. Suppression of NF-κB Signaling: A critical mechanism by which selinexor overcomes drug resistance (particularly to proteasome inhibitors) is through the nuclear retention of IκBα. In the nucleus, IκBα is protected from proteasomal degradation, allowing it to effectively bind and suppress the transcriptional activity of NF-κB, a major survival pathway for myeloma and leukemia cells [3][8].
4. Glucocorticoid Receptor Activation: Selinexor enhances the nuclear levels and transcriptional activity of the glucocorticoid receptor (GR), which synergizes with corticosteroids like dexamethasone to repress mTORC1 signaling [4][8].
4. Structure-Activity Relationship (SAR)
Selinexor belongs to a family of SINE compounds designed as N-azolylacrylate derivatives [8]. The structural hallmark of these compounds is their ability to specifically bind to the Cys528 residue located within the cargo-binding groove of the XPO1/CRM1 protein [5].
The nature of this binding is critical to selinexor's clinical viability. Early nuclear export inhibitors, such as Leptomycin B, bound to XPO1 irreversibly. This irreversible blockade crippled nuclear export in both malignant and normal cells, resulting in severe, dose-limiting toxicities (e.g., profound anorexia and malaise) that halted clinical development [3][5]. In contrast, the covalent bond formed by selinexor and other SINE compounds is slowly reversible. This transient target inhibition allows normal cells to recover from temporary cell cycle arrest once the drug is cleared, thereby significantly improving the therapeutic window and enabling systemic administration [3][4].
5. Current Limitations
The primary limitation of selinexor is its toxicity profile, which requires rigorous dose management and supportive care. Because XPO1 is essential for normal cellular functions, systemic inhibition leads to several adverse events:
Hematological Toxicities: Thrombocytopenia is the most common and dose-limiting hematological adverse event, occurring in up to 73% of patients [4]. Mechanistically, selinexor-induced thrombocytopenia results from the inhibition of thrombopoietin (TPO) signaling, which blocks the differentiation of stem cells into mature megakaryocytes [3][10]. Neutropenia and anemia are also frequently observed [4].
Non-Hematological Toxicities: Gastrointestinal and constitutional symptoms are highly prevalent. These include nausea (up to 73%), vomiting, diarrhea, anorexia, weight loss, and fatigue [7][8]. Grade 3 hyponatremia is also reported in approximately 22% of patients [3].
Management: To mitigate these toxicities, clinical practice has shifted from twice-weekly to once-weekly dosing regimens (as seen in the BOSTON and STOMP trials), which improves tolerability without sacrificing efficacy [4][7]. Aggressive prophylactic supportive care is mandatory, including the use of 5-HT3 receptor antagonists, olanzapine, TPO-mimetics (e.g., romiplostim or eltrombopag), and intravenous hydration [4][7].
6. Future Perspectives
The future of selinexor and XPO1 inhibition lies in optimizing combination therapies and developing next-generation compounds. Ongoing trials are evaluating selinexor in combination with targeted agents like venetoclax (a BCL-2 inhibitor), proteasome inhibitors, and immunotherapies (including CAR-T cells and bispecific antibodies) to overcome resistance and enhance T-cell fitness in the tumor microenvironment [8][10].
To address the toxicity limitations of selinexor, second-generation SINE compounds such as eltanexor (KPT-8602) have been developed. Eltanexor is rationally designed to have minimal blood-brain barrier penetration, which significantly reduces central nervous system-mediated toxicities (like anorexia and weight loss) while maintaining potent anti-leukemic and anti-myeloma activity [1][3].
Finally, while current literature heavily emphasizes multiple myeloma and acute leukemias, the profound effect of XPO1 inhibition on myeloid progenitor cells and megakaryopoiesis (as evidenced by its mechanism of inducing thrombocytopenia) provides a strong biological rationale for investigating SINE compounds in other myeloproliferative neoplasms. Future research directing selinexor or eltanexor toward myelofibrosis could explore whether modulating nuclear export can disrupt the aberrant megakaryocyte proliferation and cytokine release that drive bone marrow fibrosis in this disease.
